APLDQ-cβ3-E2-Fc

APLDQ-cβ3-E2-Fc is a chimeric HPA-1a-containing Fc fusion protein designed as a targeted immunotherapy for fetal and neonatal alloimmune thrombocytopenia (FNAIT). It is composed of an α-subunit-independent murine single-chain chimeric β3 integrin fragment (cβ3-E2) that incorporates five humanized amino acids (A30, P32, L33, D39, Q47) to express the human HPA-1a epitope, fused to the Fc region of mouse IgG2a. The therapeutic mechanism involves selectively neutralizing and clearing circulating maternal anti-HPA-1a alloantibodies and depleting HPA-1a-specific antibody-producing B cells. By targeting the root cause of pathogenic alloantibody generation, APLDQ-cβ3-E2-Fc aims to provide an antigen-specific alternative to non-specific immunosuppressive treatments like IVIG or FcRn-blocking antibodies.

Other names

APLDQ-cbeta3-E2-FcAPLDQ-cbeta-3-E2-FcAPLDQ-cbeta 3-E2-FcHPA-1a-containing Fc fusion proteinHPA1a-containing Fc fusion proteinHPA 1a-containing Fc fusion protein